Most Clicked StoriesMore >


Novartis' purchase of GSK's oncology business gets EU clearance

BIO SmartBrief | Jan 29, 2015

Novartis' acquisition of GlaxoSmithKline's oncology unit has been approved by the European Commission on the condition that Novartis sell its cancer therapies LGX818 and MEK162. Last year, the two drugmakers agreed to form a consumer health care venture and exchange assets worth more than $20 billion. Reuters (01/28)


Report: FDA, industry increasingly open to judging new drugs by value

BIO SmartBrief | Jan 28, 2015

House lawmakers unveil draft of 21st Century Cures Initiative

BIO SmartBrief | Jan 29, 2015

Hypoparathyroidism drug from NPS Pharmaceuticals wins FDA approval

BIO SmartBrief | Jan 26, 2015

Bill would grant 5-year exclusivity to older combo drugs

BIO SmartBrief | Jan 27, 2015

MedImmune to collaborate with National Cancer Institute on immunotherapies, technologies

BIO SmartBrief | Jan 26, 2015

FDA to expedite review of cholesterol drug from Regeneron, Sanofi

BIO SmartBrief | Jan 26, 2015

New formulation of Shire's Hunter syndrome drug wins FDA fast-track status

BIO SmartBrief | Jan 28, 2015

FDA OKs Rockwell's iron-replacement drug for hemodialysis patients

BIO SmartBrief | Jan 27, 2015

Novartis' vaccine for serogroup B meningococcal disease wins FDA nod

BIO SmartBrief | Jan 26, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the BIO Asia International Conference!

BIO SmartBrief | Jan 30, 2015

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Jan 29, 2015

Industrial biotechnology with a French twist!

BIO SmartBrief | Jan 28, 2015

Registration is open for the BIO CEO & Investor Conference!

BIO SmartBrief | Jan 27, 2015

Fall 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Jan 26, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more